Press Releases
Date Title and Summary View
Dec 22, 2014 SUNNYVALE, Calif., Dec. 22, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) announced today that the U.S Food and Drug Administration (FDA) has provided a Prescription Drug User Fee Act (PDUFA) target date of April 17, 2015 by which time the FDA is planning to finalize its review of a supplemental New Drug Application (sNDA) for IMBRUVICA (...
Dec 12, 2014 SUNNYVALE, Calif., Dec. 12, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it has been awarded BayBio's 2014 Pantheon DiNA™ Award for Outstanding Company for its rapid development and commercialization of IMBRUVICA® (ibrutinib). The award was presented at BayBio's 11th Annual Pantheon DiNA Awards ceremony in...
Dec 9, 2014 SAN FRANCISCO, Dec. 9, 2014 /PRNewswire/ -- New, 27-month IMBRUVICA® (ibrutinib) median follow-up data announced by Pharmacyclics, Inc. (NASDAQ: PCYC) today support the use of IMBRUVICA over longer periods of time in patients with relapsed/refractory mantle cell lymphoma (MCL), an aggressive type of lymphoma. More than 30% of IMBRUVICA patient...
Dec 9, 2014 SAN FRANCISCO, Dec. 9, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced new, longer term data in IMBRUVICA® (ibrutinib) patients with relapsed/refractory chronic lymphocytic leukemia (CLL), including high-risk CLL patients with deletion 17p (del 17p). Results from the Phase III RESONATE™ (PCYC-1112) trial demonstra...
Dec 9, 2014 SAN FRANCISCO, Dec. 9, 2014 /PRNewswire/ -- New IMBRUVICA® (ibrutinib) Phase II data announced by Pharmacyclics, Inc. (NASDAQ: PCYC) today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in...
Dec 8, 2014 SAN FRANCISCO, Dec. 8, 2014 /PRNewswire/ -- New, 27-month IMBRUVICA® (ibrutinib) median follow-up data announced by Pharmacyclics, Inc. (NASDAQ: PCYC) today support the use of IMBRUVICA over longer periods of time in patients with relapsed/refractory mantle cell lymphoma (MCL), an aggressive type of lymphoma. More than 30% of IMBRUVICA patient...
Dec 8, 2014 SAN FRANCISCO, Dec. 8, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced new, longer term data in IMBRUVICA® (ibrutinib) patients with relapsed/refractory chronic lymphocytic leukemia (CLL), including high-risk CLL patients with deletion 17p (del 17p). Results from the Phase III RESONATE™ (PCYC-1112) trial demonstra...
Dec 8, 2014 SAN FRANCISCO, Dec. 8, 2014 /PRNewswire/ -- New IMBRUVICA® (ibrutinib) Phase II data announced by Pharmacyclics, Inc. (NASDAQ: PCYC) today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in...
Dec 6, 2014 SAN FRANCISCO, Dec. 6, 2014 /PRNewswire/ -- New IMBRUVICA® (ibrutinib) Phase II data announced here today by Pharmacyclics, Inc. (NASDAQ: PCYC) during the 56th American Society of Hematology (ASH) Annual Meeting suggests that IMBRUVICA demonstrates anti-tumor activity both as a single-agent and as combination therapy in heavily pre-treated pat...
Dec 5, 2014 SUNNYVALE, Calif., Dec. 5, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced the launch of informCLL™, a large, observational, prospective registry that will explore the natural history of chronic lymphocytic leukemia (CLL), examine how IMBRUVICA® (ibrutinib) and other approved targeted therapies are being used to t...
1
... NextLast
Add to Briefcase = add release to Briefcase